The Royal College of Pharmacy Fellows
Fellowship is one of the highest honours the College can bestow upon its members, as it recognises those who have attained distinction in their pharmacy career. All Fellows are nominated by their peers and chosen by our distinguished Panel of Fellows.
We are currently reviewing the Fellowship process to align it to our new Royal College of Pharmacy structures. We will be in touch with all our members when submissions have been reopened.
Honorary Fellowship
Awarded to recognise those who have made a distinguished and distinctive contribution to pharmacy or the royal college. These Fellowships are for individuals not normally eligible for College membership.
Since 1953, the College has been authorised to award Honorary Fellowships to individuals through a supplementary Charter. The first recipient of the Honorary Fellowship was Prince Philip, the Duke of Edinburgh, who was given the award by then President E. A. Brocklehurst in May 1955.
Who is eligible?
To be awarded an Honorary Fellowship of the College, an individual must, in the opinion of the Senate, have:
- Attained distinction in a particular aspect or aspects of pharmacy
- Made a distinguishing and distinctive contribution to pharmacy or the College
- Distinguished themselves in any of the branches of knowledge referred to in the objects of the College
- Achieved eminence in public life.
How to nominate
Nominations can only be made by College members who sit on the Senate, National Pharmacy Advisory Councils, or other governing bodies. Nominations must be kept confidential.
To submit a nomination, write to the President at [email protected]
To be considered, nominations must include:
- A CV or ideally full biographical details (two pages max) of the nominee, and the reasons why the individual is worthy to be an Honorary Fellow; in particular, explain how the nominee has met at least one of the above criteria
- A CV or biography summary and citation of max 500 words
- Support from two College members.
The President will then discuss the proposed nomination with the CEO, and circulate this to the Senate for a final decision.